This network meta-analysis synthesized data from nine phase III randomized controlled trials to assess the relative efficacy of various first-line systemic therapies for unresectable hepatocellular carcinoma (HCC). The study found that combinations of immune checkpoint inhibitors (ICIs) and anti-VEGF agents, particularly atezolizumab plus bevacizumab, demonstrated the most favorable outcomes in
